“we feel good that we are progressing with CARVYKTI that we will continue to deliver quarter-over-quarter growth in 2024.”

In context

“e, in our European cell processing facilities. We are already manufacturing the first batches of CARVYKTI for clinical use this month of January. And we also have contracted additional capacity, external capacity to scale up production and increase our ability moving forward that will start mid this year. On the other hand, we have also made significant progress in the internalization and scale-up of our lentivirus production. We have increased capacity in Switzerland, in our Switzerland side. And at the same time, we continue to progress with new U.S. capacity and additions site in the Netherlands to produce our lentivirus. Late December, we received approval to expand our lentivirus capacity from 20-liter tanks to 50-liter tanks of lentivirus production in our U.S. facility. So overall, we feel good that we are progressing with CARVYKTI that we will continue to deliver quarter-over-quarter growth in 2024. And we are working towards building this $5 billion plus product and continue to transform the treatment paradigm in multiple myeloma, as we have discussed in the past, moving from treating to progression to treating to cure as we move CARVYKTI into earlier lines of therapy. Operator: Thank you. Next question is coming from Larry Biegelsen from Wells Fargo. Your line is now live. Lawrence Biegelsen: Good morning. Thanks for taking the question. Congrats to -- a nice finish to the year here. Joe or Joaquin, I'd love to hear just a general update on your M&A appetite and expand on your recent comments about Abiomed being a gateway in cardiovascular devices, which you, Joaquin, commented on earlier this month? Thanks so much for taking the question. Joseph Wolk: Yeah. So Larry, let me start,”